| FINRA.org Skip to main content

Scott Shea Comment On Regulatory Notice 22-08

I have been using inverse/leveraged funds for over 7 years now. When I started I was new to trading. I did all the research on the funds as that was my responsibility as a trader. The brokers I use all explained in great detail the risks of trading these types of funds.
Everyone should have the right to trade these types of investments. It should not be based on how much wealth you have. These are public funds and should remain that way.

James Gardner Comment On Regulatory Notice 22-08

Although I don't disagree with some regulation, I do have a hard time accepting restriction from investing in funds or stocks that I deem are acceptable to my risk appetite. If the regulation proposed would eliminate my access to these funds that I have the ability to research prior to any investment, I strongly oppose it. If the regulation would require that my investment vehicles be vetted for legitimacy and/or for misinformation, I'm all for it.

Virginia Donahue Comment On Regulatory Notice 22-08

Why has this troubling threat of severe restrictions shown up again to damage retail investors- many of whom are middle-class hard-working law-abiding Americans- by trying to take away the ONE SINGLE WAY we have to create decent financial protection and secure retirement for ourselves? The mega-money people in the Wall Street game have their insider information, algorithms, and just-this-side of legal maneuvers and methods to make the big bucks, kicking us retail investors to the side.

Michael Calwas Comment On Regulatory Notice 22-08

Over the years, I have used many of the "complex products" that are the subject of Regulatory Notice 22-08 including leveraged ETPs, inverse ETPs and options. In all cases, I did the appropriate research on these products to understand how they work and the risks associated with using them. These products have been an important part of my investment portfolio to either hedge certain positions or to leverage other positions. In all cases, if I reviewed a complex product and it was unclear to me what it was or how it worked, I simply did not include it in my investment portfolio.